Urushibara Nobuo, Kato Naoto, Adachi Ryutaro, Nakamura Yasuo, Mihara Ayumi, Uzawa Toyonobu, Kitagawa Shigeru, Hayashi Masanori, Kuroda Tatsuhiko, Sone Teruki
Department of Orthopedic Surgery, Nukada Memorial Hospital, 4-6-6 Omachi, Kamakura, Kanagawa, 248-0007 Japan.
Project for Bone Metabolic Disease, Asahi Kasei Pharma Corporation, 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo, 101-8101 Japan.
Springerplus. 2014 May 8;3:238. doi: 10.1186/2193-1801-3-238. eCollection 2014.
Teriparatide significantly increases bone mineral density (BMD) of the lumbar vertebrae and femur and has a strong effect in reducing the risk of bone fractures. However, few detailed investigations with dual-energy X-ray absorptiometry (DXA) of the effects of teriparatide on the radius have been reported; specifically, there are no reports of the use of once-weekly teriparatide. In this study, the effect of once-weekly teriparatide in increasing BMD was examined in the distal 1/10 of the radius and the distal 1/3 of the radius using a DXA system for the radius. In addition, the effect of radius positioning, especially accurate correction of rotation and inclination before and after administration of teriparatide, was evaluated in an assessment of its efficacy. It was found that when positioning was corrected, a significant increase in BMD in the distal 1/10 of the radius was observed after 6 months of once-weekly teriparatide. In the distal 1/3 of the radius, no significant increase of BMD was observed. This suggests that when DXA scans of the radius are analyzed with appropriate positioning, weekly teriparatide significantly increases BMD in the distal 1/10 of the radius, which is rich in cancellous bone.
特立帕肽可显著提高腰椎和股骨的骨矿物质密度（BMD），并在降低骨折风险方面具有显著效果。然而，关于使用双能X线吸收法（DXA）对特立帕肽对桡骨影响的详细研究报道较少；具体而言，尚无关于每周一次使用特立帕肽的报道。在本研究中，使用针对桡骨的DXA系统，检测了每周一次的特立帕肽对桡骨远端1/10和桡骨远端1/3骨密度增加的影响。此外，在评估其疗效时，还评估了桡骨定位的影响，特别是在特立帕肽给药前后对旋转和倾斜的精确校正。结果发现，当定位得到校正时，每周一次使用特立帕肽6个月后，桡骨远端1/10的骨密度显著增加。在桡骨远端1/3处，未观察到骨密度的显著增加。这表明，当以适当的定位分析桡骨的DXA扫描时，每周一次的特立帕肽可显著提高富含松质骨的桡骨远端1/10的骨密度。
